Login to Your Account

In The Clinic NEWS

SHANGHAI – The Shanghai-based joint venture Wuxi-Medimmune has received the go-ahead to start clinical trials from Chinese regulators for anti-IL-6 antibody WBP216 (MEDI5117) as a therapeutic for autoimmune and inflammatory diseases, in particular rheumatoid arthritis (RA).

Dermira Inc.’s third positive phase III trial with Cimzia in moderate to severe psoriasis turned up “market-leading type” results at the 400-mg dose, the firm’s chief development officer, Luis Peña, told BioWorld Today.

Alcobra Ltd. is yanking development of MDX in the lead indication of ADHD in adults after the phase III registration trial, MEASURE, failed to demonstrate a statistically significant difference from placebo in change from baseline of the investigator rating of Conners' Adult ADHD Rating Scales, the primary endpoint.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: